| Compounds | Topics | Title | Date |
|---|---|---|---|
| Myrcene | cancer,breast cancer in vitro via experiment | Anti-invasive effect of Beta-myrcene, a component of the essential oil from Pinus koraiensis cones, in metastatic MDA-MB-231 human breast cancer cells | Aug 2015 |
| Pretreatment with beta--myrcene suppressed TNFalpha--induced phosphorylation of inhibitor of kappa-B kinase and NF-kappa-B as well as matrix metalloproteinase-9 (MMP-9) gene expression in a dose-dependent fashion. Furthermore, beta--myrcene inhibited TNFalpha--induced invasion of MDA-MB-231 cells as determined by three-dimensional spheroid invasion assays. | |||
| ANA | cancer,breast cancer in vitro | The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation | Jun 1998 |
| These data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous prolactin action at the level of prolactin receptor. | |||
| JWH-015 | cancer,breast cancer in mice | Crosstalk between Chemokine Receptor CXCR4 and Cannabinoid Receptor CB2 in Modulating Breast Cancer Growth and Invasion | Sep 2011 |
| Furthermore, our studies have revealed that JWH-015 significantly inhibits phosphorylation of CXCR4 and its downstream signaling in vivo in orthotopic and spontaneous breast cancer MMTV-PyMT mouse model systems. | |||
| CBD | cancer,breast cancer in mice | Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. | Aug 2011 |
|
Action Pathway: Id-1 Our data demonstrate the efficacy of CBD in pre-clinical models of breast cancer. The results have the potential to lead to the development of novel non-toxic compounds for the treatment of breast cancer metastasis, and the information gained from these experiments broaden our knowledge of both Id-1 and cannabinoid biology as it pertains to cancer progression. | |||
| CBD | cancer,breast cancer in vitro | Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer | Jan 2015 |
| We show here -for the first time-that CBD significantly inhibits epidermal growth factor (EGF)-induced proliferation and chemotaxis of breast cancer cells | |||
| Geraniol | cancer,breast cancer,lung cancer via review | The antitumor effects of geraniol: Modulation of cancer hallmark pathways (Review) | May 2016 |
| Geraniol is a dietary monoterpene alcohol that is found in the essential oils of aromatic plants. To date, experimental evidence supports the therapeutic or preventive effects of geraniol on different types of cancer, such as breast, lung, colon, prostate, pancreatic, and hepatic cancer, and has revealed the mechanistic basis for its pharmacological actions. | |||
| Geraniol | cancer,breast cancer in vitro | Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. | Nov 2004 |
| These findings indicate that mechanisms other than impaired mevalonate synthesis mediate the anti-proliferative and cell cycle regulatory effects of beta-ionone and geraniol in human breast cancer cells. | |||
| THC | cancer,breast cancer in mice | Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. | Mar 2005 |
|
Action Pathway: CB2 Negative Furthermore, exposure of mice to Delta9-THC led to significantly elevated 4T1 tumor growth and metastasis due to inhibition of the specific antitumor immune response in vivo. The suppression of the antitumor immune response was mediated primarily through CB2 as opposed to CB1. | |||
| CBD,CBG,CBC | cancer,breast cancer in vitro | Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. | May 2006 |
| Results obtained in a panel of tumor cell lines clearly indicate that, of the five natural compounds tested, cannabidiol is the most potent inhibitor of cancer cell growth (IC(50) between 6.0 and 10.6 microM), with significantly lower potency in noncancer cells. The cannabidiol-rich extract was equipotent to cannabidiol, whereas cannabigerol and cannabichromene followed in the rank of potency. | |||
| THC | cancer,breast cancer in vitro | Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. | Jul 2006 |
| Here, we show that Delta(9)-tetrahydrocannabinol (THC), through activation of CB(2) cannabinoid receptors, reduces human breast cancer cell proliferation by blocking the progression of the cell cycle and by inducing apoptosis. | |||
| CBD | cancer,breast cancer in mice via model | Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. | Nov 2007 |
| In conclusion, CBD represents the first nontoxic exogenous agent that can significantly decrease Id-1 expression in metastatic breast cancer cells leading to the down-regulation of tumor aggressiveness. | |||
| THC | cancer,breast cancer in mice via experiment | JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. | Aug 2008 |
|
Action Pathway: JunD,p8 It has been recently shown that cannabinoids, the active components of marijuana and their derivatives, inhibit cell cycle progression of human breast cancer cells. Here we studied the mechanism of Delta(9)-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family | |||
| Phellandrene,Terpinolene,Cymene,Pinene | cancer, anti-inflamatory,cancer,breast cancer in vitro | Chemical composition, antimicrobial, and cytotoxicity studies on S. erianthum and S. macranthum essential oils | Apr 2012 |
| The Solanum essential oils possess strong antimicrobial activity in addition to the potent cytotoxic potential of S. erianthum leaf oil against Hs 578T and PC-3 cells. | |||
| CBD | cancer,breast cancer,prostate cancer via review | Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. | Nov 2016 |
| Cannabinoids, in particular the non-psychoactive CBD, may be promising tools in combination therapy for breast and prostate cancer, due to their direct antitumor effects, their ability to improve the efficacy of conventional antitumor drugs and their usefulness as palliative treatment. Nevertheless, deeper studies to fully establish the mechanisms responsible for their antitumour and pro-tumour properties and their formulation in efficient delivery systems remain to be established. | |||
| CBD | cancer,breast cancer in vitro via experiment | Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. | Oct 2018 |
|
Action Pathway: PPARg, mTOR and cyclin D1 Positive In both cell lines, CBD inhibited cell survival and induced apoptosis in a dose dependent manner as observed by MTT assay, morphological changes, DNA fragmentation and ELISA apoptosis assay. | |||